Head-To-Head Contrast: AtriCure (NASDAQ:ATRC) & Nyxoah (NASDAQ:NYXH)

AtriCure (NASDAQ:ATRC) and Nyxoah (NASDAQ:NYXH) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, valuation and dividends.

Profitability

This table compares AtriCure and Nyxoah’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
AtriCure	-9.61%	-6.80%	-5.19%
Nyxoah	-1,043.93%	-51.68%	-40.11%

Analyst Ratings

This is a summary of current ratings and target prices for AtriCure and Nyxoah, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AtriCure	0	0	9	0	3.00
Nyxoah	0	0	4	0	3.00

AtriCure presently has a consensus target price of $50.67, suggesting a potential upside of 46.69%. Nyxoah has a consensus target price of $14.50, suggesting a potential upside of 84.71%. Given Nyxoah’s higher probable upside, analysts plainly believe Nyxoah is more favorable than AtriCure.

Volatility and Risk

AtriCure has a beta of 1.57, suggesting that its stock price is 57% more volatile than the S&P 500. Comparatively, Nyxoah has a beta of 1.56, suggesting that its stock price is 56% more volatile than the S&P 500.

Earnings and Valuation

This table compares AtriCure and Nyxoah”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AtriCure	$480.08 million	3.56	-$44.70 million	($0.81)	-42.64
Nyxoah	$4.36 million	61.27	-$46.77 million	($2.13)	-3.69

AtriCure has higher revenue and earnings than Nyxoah. AtriCure is trading at a lower price-to-earnings ratio than Nyxoah, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

99.1% of AtriCure shares are held by institutional investors. 3.5% of AtriCure shares are held by insiders. Comparatively, 17.1% of Nyxoah shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

AtriCure beats Nyxoah on 9 of the 13 factors compared between the two stocks.

About AtriCure

AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure. In addition, the company sells Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.

About Nyxoah

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.